October 21, 2021, 18:00 - 19:30 (JST)
Online participation via Zoom
Moderators and panelists
Primary objectives and outcomes
The end of the COVID-19 pandemic remains out of sight. To overcome challenges in these times of uncertainty, Japan set the goal of leaving no one's health behind. JICA is taking a holistic approach to address issues related to the pandemic and health security in partner countries by focusing on prevention, precaution and treatment. Using this approach, it hopes to contribute to the protection of people's lives as the urgent target and build increasingly resilient societies.
Content of the discussions
In this eighth webinar, Dr. SAITO, Dr. ARYAL, and Dr. HASHMI presented a way of finding the optimal therapeutics for COVID-19 using REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia), a pandemic-responsive global research platform. REMAP-CAP is a global collaborative research platform that aims to find the optimal therapeutics for severe community-acquired pneumonia including COVID-19, at a very early stage. During the session, the speakers explained the usefulness of adaptive platform research in infectious diseases crises and discussed the significance of collaborative clinical research including low- and middle-income countries (LMICs) by introducing REMAP-CAP initiatives in Japan, Nepal, and Pakistan.
Japan International Cooperation Agency (JICA)
JICA Ogata Research Insititute for Peace and Development (Ms.Yamamoto)
This event has ended.